Sponsor

Alcon Research, Ltd.

Generic Drug Name

Brinzolamide 10 mg/mL/timolol 5 mg/mL eye drops, suspension (AZARGA®)

Trial Indication(s)

Replacement therapy in patients with uncontrolled intraocular pressure

Protocol Number

SMA-09-19-SVN

Protocol Title

Assessing the safety and efficacy of switching to AZARGA® (brinzolamide/timolol fixed combination) as replacement therapy in patients with uncontrolled intraocular pressure

Clinical Trial Phase

4

Study Start/End Dates

Study Start: 27-NOV-2009 (First Patient First Visit)

Study End: 21-JUN-2010 (Last Patient Last Visit)

Reason for Termination (if applicable)

Poor enrollment and not based on any safety concern

Study Design/Methodology

This was an interventional, prospective, multi-center, open-label, exploratory study.

Alcon

a Novartis company

Centers

This study was conducted in two study centers located in Slovenia.

Objectives

Primary Objective

The objective of this study was to assess the safety and efficacy of switching to AZARGA® from prior pharmacotherapy in patients with open-angle glaucoma or ocular hypertension.

Test Product (s), Dose(s), and Mode(s) of Administration

Test Product: Brinzolamide 10 mg/mL/timolol 5 mg/mL eye drops, suspension (AZARGA®)

Dosage: 1 drop twice daily (BID) in the study eye for up to 8 weeks

Mode of Administration: topical ocular

Statistical Methods

The primary efficacy variable was planned to be analyzed using paired t-test.

Study Population: Key Inclusion/Exclusion Criteria

Inclusion criteria:

- Must be at least 18 years of age;
- Clinical diagnosis of ocular hypertension, primary open-angle or pigment dispersion glaucoma in both eyes;
- Must have an IOP of between 19 to 35 mmHg in at least one eye (which would be the study eye). In the eye that is not included in the study, the IOP should be able to be controlled on no pharmacologic therapy or on the study medicine alone.
- On a stable regimen intraocular pressure (IOP) lowering within 1 week of the Screening Visit;
- Willing to discontinue the use of all other ocular hypotensive medications prior to receiving the study medication for the entire course of the study;
- Best corrected visual acuity of 6/60 (20/200 Snellen, 1.0 LogMAR) or better in each eye.

Exclusion criteria:

- Known medical history of allergy, hypersensitivity or poor tolerance to any components of the preparations used in this study;
- Eye conditions/infections/surgeries and/or medical conditions, as specified in the protocol;

- Use of medications, as specified in the protocol;
- Women who are pregnant, lactating, or of child-bearing potential;

Participant Flow Table (Intent to Treat)

Disposition Reason	AZARGA® N=21 n (%)
Completed study	21 (100.0)
Did not complete study	0
Primary reason for not completing study	
Lost to follow-up	0
AEs	0
Other	0

AE = adverse event

- Percentages were computed using the number of patients in the Intent-to-treat set as denominator.
- Patients who attended Visit 4 (Week 6 to 8, Exit) were considered as completing the study.
- Patients who exited the study before completing Visit 4 (Week 6 to 8, Exit) were considered as not completing the study.

Alcon
a Novartis company

Baseline Characteristics (Intent to Treat)

Demographic variable	AZARGA® N=21
Age (years)	
n	21
Mean (SD)	69.7 (13.32)
Median	74.0
Min, Max	44, 88
Age category - n (%)	
18 to 64 years	7 (33.3)
65 to 84 years	12 (57.1)
≥ 85 years	2 (9.5)
Gender - n (%)	
Female	11 (52.4)
Male	10 (47.6)
Ethnicity - n (%)	
White	3 (14.3)
Black	0
Asian	0
Hispanic	0
Other	0
Missing	18 (85.7)

Min = minimum, Max = maximum, SD = standard deviation

Summary of Efficacy

Primary Outcome Result(s)

No meaningful conclusions can be made from this early terminated study with regard to efficacy, due to the small sample size.

Mean intra-ocular pressure (mmHg) and mean intra-ocular pressure change from baseline at Week 6 to 8 from prior Cosopt® therapy (Per-protocol set)

Statistic	AZARGA® (N=19)		
	Mean IOP at Baseline	Mean IOP at Week 6-8	IOP change from Baseline to Week 6-8
n	12	12	12
Mean (SD)	19.8 (0.97)	18.0 (1.21)	−1.8 (1.42)
Median	20.0	18.0	−2.0
Min, Max	18, 21	16, 20	−4, 0

IOP = intraocular pressure, Min = minimum, Max = maximum, SD = standard deviation

- Only patients with prior Cosopt® therapy (Visit 1) were included in the analysis.

Secondary Outcome Result(s)

Frequency and percentage of patients at target intraocular pressure (≤ 18 mmHg) at Week 6 to 8, regardless of prior therapy – Per-protocol set

Variable	AZARGA® (N=19) n (%)
IOP ≤ 18 mmHg	13 (68.4)
IOP > 18 mmHg	6 (31.6)

IOP = intraocular pressure

Summary of Safety

With regard to safety, AZARGA® was well-tolerated over the period of up to 8 weeks, with no adverse events reported during the study.

Serious Adverse Events by System Organ Class

None

Other Adverse Events by System Organ Class

None

Other Relevant Findings

None

Alcon

a Novartis company

Date of Clinical Trial Report

13-Sep-2018